eCite Digital Repository

Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease modifying therapy prescription data


Campbell, JA and Simpson Jr, S and Ahmad, H and Taylor, BV and van der Mei, I and Palmer, AJ, Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease modifying therapy prescription data, Multiple Sclerosis Journal, 26, (11) pp. 1315-1328. ISSN 1352-4585 (2020) [Refereed Article]

Copyright Statement

© The Author(s), 2019.

Official URL:

DOI: doi:10.1177/1352458519861270


Objective: Determine the prevalence of multiple sclerosis (MS) in Australia in 2017 using MS-specific disease-modifying therapy (DMT) prescription data and estimate the change in prevalence from 2010.

Methods: DMT prescriptions were extracted from Australia’s Pharmaceutical Benefits Scheme (PBS) data for January-December 2017. Percentages of people with MS using DMTs (DMT penetrance) were calculated using data from the Australian MS Longitudinal Study. Prevalence was estimated by dividing the total number of monthly prescriptions by 12 (except alemtuzumab), adjusted for DMT penetrance and Australian population estimates. Prevalences in Australian states/territories were age-standardised to the Australian population. Comparisons with 2010 prevalence data was performed using Poisson regression.

Results: Overall DMT penetrance was 64%, and the number of people with MS in Australia in 2017 was 25,607 (95% CI: 24,874-26,478), a significant increase of 4,324 people since 2010 (p<0.001). The prevalence increased significantly from 95.6/100,000 (2010) to 103.7/100,000 (2017), with estimates highest in Tasmania in 2017 (138.7/100,000; 95% CI: 137.2-140.1) and lowest in Queensland (74.6/100,000; 95% CI: 73.5-75.6). We also found an average 3% increase in prevalence from 2010 to 2017 per one degree increase in latitude.

Conclusion: Consistent with global trends, Australia’s MS prevalence has increased, this probably reflecting decreased mortality, increased longevity and increased incidence.

Item Details

Item Type:Refereed Article
Keywords:Australian Multiple Sclerosis Longitudinal Study, Australian Pharmaceutical Benefits Scheme, immunomodulating agent, health economics
Research Division:Health Sciences
Research Group:Epidemiology
Research Field:Epidemiology not elsewhere classified
Objective Division:Health
Objective Group:Public health (excl. specific population health)
Objective Field:Public health (excl. specific population health) not elsewhere classified
UTAS Author:Campbell, JA (Dr Julie Campbell)
UTAS Author:Simpson Jr, S (Dr Steve Simpson JR)
UTAS Author:Ahmad, H (Mr Hasnat Ahmad)
UTAS Author:Taylor, BV (Professor Bruce Taylor)
UTAS Author:van der Mei, I (Professor Ingrid van der Mei)
UTAS Author:Palmer, AJ (Professor Andrew Palmer)
ID Code:132907
Year Published:2020 (online first 2019)
Web of Science® Times Cited:11
Deposited By:Menzies Institute for Medical Research
Deposited On:2019-05-27
Last Modified:2021-03-23
Downloads:3 View Download Statistics

Repository Staff Only: item control page